Condition
Angiokeratomas
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Recruiting1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07552077Phase 2RecruitingPrimary
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
NCT02778295WithdrawnPrimary
Biomarker for Patients With Fabry Disease (BioFabry)
Showing all 2 trials